The quest for CJC-1295 in Oizé inevitably reaches the same conclusion: research peptides are supplied via specialist online vendors, not local pharmacies. This concentration of supply in online vendors is actually an advantage for quality — top vendors compete on lab-verified purity in ways brick-and-mortar outlets simply cannot. Separating quality CJC-1295 from the rest of the market comes down to three things: an HPLC chromatogram documenting ≥98% purity, mass spec data establishing the correct molecular weight, and a batch-specific endotoxin panel. Use this guide to verify vendor quality systematically — the framework here work regardless of your location.
The Science Behind CJC-1295
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Oizé researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
Quality CJC-1295 sourcing begins with a simple filter: does this vendor make batch-matched COAs available before purchase? Those who make this data freely available are demonstrating research-grade standards. Endotoxin testing in the COA is critical for any injectable research use — endotoxins from microbial contamination can trigger severe inflammatory responses even at very low concentrations. For Oizé researchers evaluating vendors with limited track records: a small initial order to verify quality before placing larger orders is the accepted approach among experienced researchers. Store lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the quantity required for your immediate research and keep the remainder frozen.
Order CJC-1295 — ships to Oizé
COA-verified · International tracking · Research grade
CJC-1295 is sold for research purposes only and is not approved for human therapeutic use by the FDA or equivalent agencies worldwide — all information here is educational. Storage requirements for CJC-1295: lyophilised powder at −20°C, reconstituted solution stored refrigerated at 2-8°C and consumed within 4 weeks; reconstitute only with sterile bacteriostatic water. Endotoxin testing in the CJC-1295 COA is non-negotiable — gram-negative bacterial endotoxins can trigger severe inflammatory responses at very low concentrations, and no cost saving makes omitting this acceptable. PubMed are the primary literature resources for CJC-1295 research; prioritise peer-reviewed studies with characterised source material over unreviewed preprints or forum reports.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
